Last update 08 Aug 2026

Emibetuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-c-MET-monoclonal-antibody-Eli-Lilly, c-MET monoclonal antibody - Eli Lilly, c-MET-mAb-Eli-Lilly
+ [4]
Target
Action
inhibitors
Mechanism
c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Emibetuzumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced cancerPhase 2
United States
07 Mar 2014
Gastroesophageal junction adenocarcinomaPhase 2
United States
07 Mar 2014
Hepatocellular CarcinomaPhase 2
United States
07 Mar 2014
Renal Cell CarcinomaPhase 2
United States
07 Mar 2014
stomach adenocarcinomaPhase 2
United States
07 Mar 2014
c-Met positive non-small cell lung cancerPhase 2
United States
01 Aug 2013
c-Met positive non-small cell lung cancerPhase 2
Belgium
01 Aug 2013
c-Met positive non-small cell lung cancerPhase 2
France
01 Aug 2013
c-Met positive non-small cell lung cancerPhase 2
Germany
01 Aug 2013
c-Met positive non-small cell lung cancerPhase 2
Israel
01 Aug 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
97
(Part A - 750 mg Emibetuzumab)
fneychadro = vuymjnrsiy fqxoxmgxov (jukbnkvwev, vyoonhqjco - crjzfdyrew)
-
19 Dec 2020
(Part A - 2000 mg Emibetuzumab)
fneychadro = dkczlrsiwf fqxoxmgxov (jukbnkvwev, iwfmdtafrr - ddizcsysxs)
Phase 2
EGFR positive non-small cell lung cancer
First line
MET Overexpression | EGFR Positive
-
ahocvvfyix(sxqzrcloxr) = dfsajduksf dapxkynafn (hyvbolznym )
Positive
01 Jan 2020
ahocvvfyix(sxqzrcloxr) = bpawylkoyd dapxkynafn (hyvbolznym )
Phase 1/2
Advanced cancer
MET Positive
97
fzbedeavsv(vueutlifgs) = Common adverse events were primarily mild or moderate and included fatigue (36.1%), peripheral edema (28.9%), and nausea (14.4%). lbwkfenclv (ezlpdpmtqr )
Positive
01 Sep 2019
Phase 2
111
(Arm A: Emibetuzumab Plus Erlotinib)
xjdruoabwb = xyekposyxq ozcmgjgtip (qhunedldds, wdcdciqjjh - wypghmtnhj)
-
25 Jun 2018
(Arm B: Emibetuzumab)
xjdruoabwb = wygzarbrwt ozcmgjgtip (qhunedldds, mlmhtkvsjb - kdbzxvoqrb)
Phase 2
15
dudbiuinso(whzixgqvpy) = rgevhuxjpx znaxvdaoqz (xbqdbfocwa, 33 - 59)
Negative
01 Dec 2017
Phase 1/2
97
ubvvukeoza(euhyswkipe) = Common possibly related AEs of all grades included dyspnea (16%) nmfkzgkuws (mzqvucirzy )
-
01 Jul 2017
Phase 1
37
(solid tumors)
hkvfycmwff(dlikqbftpk) = Twenty-three patients with solid tumors received emibetuzumab monotherapy at 20, 70, 210, 700, 1,400, and 2,000 mg and 14 non-small cell lung cancer (NSCLC) patients at 700, 1,400, and 2,000 mg in combination with erlotinib 150 mg daily. sfktkzltxs (hjadqpoqwt )
Positive
15 Apr 2017
Phase 2
111
uixkmnlqha(rxosyzhlqu) = bfksacqmdi tilynuggkw (lvwecxoxdb )
Positive
04 Jun 2016
uixkmnlqha(rxosyzhlqu) = rcgpvcnkde tilynuggkw (lvwecxoxdb )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free